RYVU Therapeutics S.A.

Major Shareholding Notification • May 6, 2025

Report Content Receipt of a notification under Article 69 of the Public Offering Actfrom TFI Allianz Polska S.A. regarding the decrease below the 5%threshold of the total number of votes in the Company

The Management Board of Ryvu Therapeutics S.A., with its registeredoffice in Kraków (the "Company"), hereby informs that on May 2, 2025 itreceived a notification from TFI Allianz Polska S.A., acting on behalfof the following funds: Allianz FIO, Allianz Inwestycje SFIO, AllianzPlan Emerytalny SFIO, and Bezpieczna Jesień SFIO (the "Funds"), preparedin accordance with Article 69(1)(1) and Article 87(1)(2)(a) of the Actof 29 July 2005 on Public Offering, Conditions Governing theIntroduction of Financial Instruments to Organized Trading, and PublicCompanies, regarding a decrease below the 5% threshold of the totalnumber of votes at the Company's General Meeting.

According to the content of the notification, as a result of a saletransaction of the Company's shares carried out on 28 April 2025(settlement date: 30 April 2025), the total share of the Funds in thetotal number of votes at the General Meeting of the Company decreasedbelow the 5% threshold and currently amounts to 4.96%.

The full content of the notification is attached to this report.